Matches in SemOpenAlex for { <https://semopenalex.org/work/W2416677788> ?p ?o ?g. }
Showing items 1 to 74 of
74
with 100 items per page.
- W2416677788 endingPage "8" @default.
- W2416677788 startingPage "65" @default.
- W2416677788 abstract "A group of patients with severe peripheral vascular disease has been treated with PGE1 alpha-ciclodestrina (as reported in the previous 9 articles) including 595 patients (mean age 64.52 +/- 12; 307 with intermittent claudication and 237 with critical limb ischemia, rest pain and gangrene). Also 51 diabetics were studied and treated (25% with claudication and the remaining group with critical ischemia and/or neuropathy). The mean dosage administered in most patients (83% were treated with the short-term protocol) had been 20 + 40 micrograms on the first day and 60 + 40 micrograms on the second day.Subjects had been treated on average 2.6 times (cycles of short term treatment); 37% of patients had received at least 3 cycles of short term treatment. Clinically relevant side effects have been observed in 30 patients (5% of the 595 treated patients). Temporary suspension of treatment has reduced/abolished side effects in 18 out of 30 patients and only in 5 patients (0.8%) therapy had to be suspended. Clinical improvement was evaluated according to subjective improvement, objective improvement (as defined by the treating physician/surgeon) and one or more physiological parameters (flux, flow, treadmill test). Among patients with intermittent claudication (only considered endpoint was walking distance) 78% was significantly improved. In patients with critical ischemia (endpoints were pain control, decrease of ischemic areas and perfusion improvement, objectively measured) 66% of patients improved. In diabetics (including both claudicants and subjects with critical ischemia) 58% improved.Global analysis of the previous 9 studies indicates that PGE1 alpha-ciclodestrina treatment is effective, there are few and controllable (in most patients) side effects and the treatment (particularly the short term protocol) is very cost effective." @default.
- W2416677788 created "2016-06-24" @default.
- W2416677788 creator A5000733414 @default.
- W2416677788 creator A5013333198 @default.
- W2416677788 creator A5032439447 @default.
- W2416677788 creator A5060170894 @default.
- W2416677788 creator A5068969598 @default.
- W2416677788 creator A5081342232 @default.
- W2416677788 date "1998-10-01" @default.
- W2416677788 modified "2023-09-23" @default.
- W2416677788 title "[Global analysis of data from studies with PDE1 alpha-cyslodextrin]." @default.
- W2416677788 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/10658448" @default.
- W2416677788 hasPublicationYear "1998" @default.
- W2416677788 type Work @default.
- W2416677788 sameAs 2416677788 @default.
- W2416677788 citedByCount "0" @default.
- W2416677788 crossrefType "journal-article" @default.
- W2416677788 hasAuthorship W2416677788A5000733414 @default.
- W2416677788 hasAuthorship W2416677788A5013333198 @default.
- W2416677788 hasAuthorship W2416677788A5032439447 @default.
- W2416677788 hasAuthorship W2416677788A5060170894 @default.
- W2416677788 hasAuthorship W2416677788A5068969598 @default.
- W2416677788 hasAuthorship W2416677788A5081342232 @default.
- W2416677788 hasConcept C126322002 @default.
- W2416677788 hasConcept C141071460 @default.
- W2416677788 hasConcept C146957229 @default.
- W2416677788 hasConcept C168563851 @default.
- W2416677788 hasConcept C203092338 @default.
- W2416677788 hasConcept C2776626339 @default.
- W2416677788 hasConcept C2777466421 @default.
- W2416677788 hasConcept C2778963770 @default.
- W2416677788 hasConcept C2779881954 @default.
- W2416677788 hasConcept C2781099653 @default.
- W2416677788 hasConcept C2781464450 @default.
- W2416677788 hasConcept C3018348675 @default.
- W2416677788 hasConcept C42219234 @default.
- W2416677788 hasConcept C541997718 @default.
- W2416677788 hasConcept C71924100 @default.
- W2416677788 hasConceptScore W2416677788C126322002 @default.
- W2416677788 hasConceptScore W2416677788C141071460 @default.
- W2416677788 hasConceptScore W2416677788C146957229 @default.
- W2416677788 hasConceptScore W2416677788C168563851 @default.
- W2416677788 hasConceptScore W2416677788C203092338 @default.
- W2416677788 hasConceptScore W2416677788C2776626339 @default.
- W2416677788 hasConceptScore W2416677788C2777466421 @default.
- W2416677788 hasConceptScore W2416677788C2778963770 @default.
- W2416677788 hasConceptScore W2416677788C2779881954 @default.
- W2416677788 hasConceptScore W2416677788C2781099653 @default.
- W2416677788 hasConceptScore W2416677788C2781464450 @default.
- W2416677788 hasConceptScore W2416677788C3018348675 @default.
- W2416677788 hasConceptScore W2416677788C42219234 @default.
- W2416677788 hasConceptScore W2416677788C541997718 @default.
- W2416677788 hasConceptScore W2416677788C71924100 @default.
- W2416677788 hasIssue "10 Suppl 1" @default.
- W2416677788 hasLocation W24166777881 @default.
- W2416677788 hasOpenAccess W2416677788 @default.
- W2416677788 hasPrimaryLocation W24166777881 @default.
- W2416677788 hasRelatedWork W2061155848 @default.
- W2416677788 hasRelatedWork W2078591307 @default.
- W2416677788 hasRelatedWork W2084679456 @default.
- W2416677788 hasRelatedWork W2116041544 @default.
- W2416677788 hasRelatedWork W2383725167 @default.
- W2416677788 hasRelatedWork W2416677788 @default.
- W2416677788 hasRelatedWork W2436189237 @default.
- W2416677788 hasRelatedWork W277414802 @default.
- W2416677788 hasRelatedWork W69621217 @default.
- W2416677788 hasRelatedWork W2527463142 @default.
- W2416677788 hasVolume "46" @default.
- W2416677788 isParatext "false" @default.
- W2416677788 isRetracted "false" @default.
- W2416677788 magId "2416677788" @default.
- W2416677788 workType "article" @default.